The landscape of EGFR pathways and personalized management of non-small-cell lung cancer

By Cheng Liang   Zhang Shaobo   Alexander Riley   Yao Yongxue   MacLennan Gregory T   Pan Chong-xian   Huang Jiaoti   Wang Mingsheng   Montironi Rodolfo   Lopez-Beltran Antonio  

Future Oncology, Vol. 7, Iss. 4, 2011-04 ,pp. : 519-541

Future Medicine

Access to resources Recommend Favorite

Suppression of Epidermal Growth Factor Receptor (EGFR) Expression by Small Hairpin RNA Inhibits the Growth of Human Nonsmall Cell Lung Cancers Bearing Wild-type and Mutant EGFR

By Zhang Shuang   Tian Hongwei   Jiang Qingyuan   Li Li   Ding Yu   Dai Lei   Xiang Yu   Shen Guobo   Cheng Lin   Huang Qiaorong   Liu Yalin   Zhang Xiaomei   Ma Yongping   Zhang Na   Liu Shengyong   Wang Wei   Dai Lixia   Li Yiming   Zhao Xia   Wei Yuquan   Deng Hongxin  

Cancer Investigation, Vol. 29, Iss. 10, 2011-11 ,pp. : 701-708

Informa Healthcare

Access to resources Recommend Favorite

The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors

By Belani Chandra P.  

Cancer Investigation, Vol. 28, Iss. 4, 2010-04 ,pp. : 413-423

Informa Healthcare

Access to resources Recommend Favorite

BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer

By Li Zhanxia  

Medical Oncology, Vol. 28, Iss. 2, 2011-06 ,pp. : 572-577

Humana Press, Inc

Access to resources Recommend Favorite

Continuous exposure of nonsmall cell lung cancer cells with wildtype EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3

By                  

International Journal of Oncology, Vol. 46, Iss. 5, 2015-01 ,pp. : 2083-2095

Spandidos Publications

Access to resources Recommend Favorite